Pharmacological Immunosuppression Reduces But Does Not Eliminate the Need for Total-Body Irradiation in Nonmyeloablative Conditioning Regimens for Hematopoietic Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 8, 2011, Pages 1255-1260

  Mielcarek, Marco ^a   Torok Storb, Beverly ^a   Storb, Rainer ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Canine model; Hematopoietic cell transplantation; Immunosuppression; Mixed chimerism; Nonmyeloablative conditioning; Tolerance

Indexed keywords

CYCLOSPORIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENILEUKIN DIFTITOX; FLT3 LIGAND; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ARTICLE; CELL EXPANSION; CONTROLLED STUDY; DENDRITIC CELL; DONOR; ENGRAFTMENT; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; IMMUNOMODULATION; IN VIVO STUDY; NONHUMAN; NONMYELOABLATIVE CONDITIONING; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; T LYMPHOCYTE; WHOLE BODY RADIATION;

ANIMALS; DISEASE MODELS, ANIMAL; DOGS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; MALE; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; WHOLE-BODY IRRADIATION;

EID: 79960204137     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.01.003     Document Type: Article

References (24)

1. McSweeney P.A., Niederwieser D., Shizuru J.A., et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001, 97:3390-3400.
2. Storb R., Yu C., Wagner J.L., et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997, 89:3048-3054.
3. Upton A.C., Shore R.E., Harley N.H. The health effects of low-level ionizing radiation. Annu Rev Public Health 1992, 13:127-150.
4. Brenner D.J., Doll R., Goodhead D.T., et al. Cancer risks attributable to low doses of ionizing radiation: assessing what we really know. Proc Natl Acad Sci U S A 2003, 100:13761-13766.
5. Miale T.D., Sirithorn S., Ahmed S. Efficacy and toxicity of radiation in preparative regimens for pediatric stem cell transplantation. II: Deleterious consequences. Med Oncol 1996, 13:43-61.
6. Locatelli F., Giorgiani G., Pession A., Bozzola M. Late effects in children after bone marrow transplantation: a review. Haematologica 1993, 78:319-328.
7. Zaucha J.M., Zellmer E., Georges G., et al. G-CSF-mobilized peripheral blood mononuclear cells added to marrow facilitates engraftment in nonmyeloablated canine recipients: CD3 cells are required. Biol Blood Marrow Transplant 2001, 7:613-619.
8. Storb R., Yu C., Barnett T., et al. Stable mixed hematopoietic chimerism in dog leukocyte antigen-identical littermate dogs given lymph node irradiation before and pharmacologic immunosuppression after marrow transplantation. Blood 1999, 94:1131-1136.
9. Jochum C., Beste M., Zellmer E., Graves S.S., Storb R. CD154 blockade and donor-specific transfusions in DLA-identical marrow transplantation in dogs conditioned with 1-Gy total body irradiation. Biol Blood Marrow Transplant 2007, 13:164-171.
10. Wagner J.L., Burnett R.C., DeRose S.A., Francisco L.V., Storb R., Ostrander E.A. Histocompatibility testing of dog families with highly polymorphic microsatellite markers. Transplantation 1996, 62:876-877.
11. Wagner J.L., Burnett R.C., Works J.D., Storb R. Molecular analysis of DLA-DRBB1 polymorphism. Tissue Antigens 1996, 48:554-561.
12. Sandmaier B.M., Storb R., Santos E.B., et al. Allogeneic transplants of canine peripheral blood stem cells mobilized by recombinant canine hematopoietic growth factors. Blood 1996, 87:3508-3513.
13. Jochum C., Beste M., Zellmer E., Graves S.G., Storb R. Donor-specific mononuclear cell transfusion and methotrexate as pretransplant treatment in dogs given DLA-identical marrow grafts after nonmyeloablative conditioning. Biol Blood Marrow Transplant 2006, 12:885-886.
14. Mielcarek M., Kucera K.A., Nash R.A., Torok-Storb B., McKenna H.J. Identification and characterization of canine dendritic cells generated in vivo. Biol Blood Marrow Transplant 2007, 13:1286-1293.
15. Yu C., Ostrander E., Bryant E., Burnett R., Storb R. Use of (CA)n polymorphisms to determine the origin of blood cells after allogeneic canine marrow grafting. Transplantation 1994, 58:701-706.
16. Hilgendorf I., Weirich V., Zeng L., et al. Canine haematopoietic chimerism analyses by semiquantitative fluorescence detection of variable number of tandem repeat polymorphism. Vet Res Commun 2005, 29:103-110.
17. Storb R., Yu C., Zaucha J.M., et al. Stable mixed hematopoietic chimerism in dogs given donor antigen, CTLA4Ig, and 100 cGy total body irradiation before and pharmacologic immunosuppression after marrow transplant. Blood 1999, 94:2523-2529.
18. Sorror M.L., Leisenring W., Mielcarek M., et al. Intensified postgrafting immunosuppression failed to assure long-term engraftment of dog leukocyte antigen-identical canine marrow grafts after 1 gray total body irradiation. Transplantation 2008, 85:1023-1029.
19. Kahl C., Mielcarek M., Iwata M., Harkey M.A., Storer B., Torok-Storb B. Radiation dose determines the degree of myeloid engraftment following nonmyeloablative stem cell transplantation. Biol Blood Marrow Transplant 2004, 10:826-833.
20. Antoine C., Muller S., Cant A., et al. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99. Lancet 2003, 361:553-560.
21. Burroughs L.M., Storb R., Leisenring W.M., et al. Intensive postgrafting immune suppression combined with nonmyeloablative conditioning for transplantation of HLA-identical hematopoietic cell grafts: results of a pilot study for treatment of primary immunodeficiency disorders. Bone Marrow Transplant 2007, 40:633-642.
22. Yunusov M.Y., Georges G.E., Storb R., et al. FLT3 ligand promotes engraftment of allogeneic hematopoietic stem cells without significant graft-versus-host disease. Transplantation 2003, 75:933-940.
23. Shlomchik W.D., Couzens M.S., Tang C.B., et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999, 285:412-415.
24. Mielcarek M., Georges G.E., Storb R. Denileukin diftitox as prophylaxis against graft-versus-host disease in the canine hematopoietic cell transplantation model. Biol Blood Marrow Transplant 2006, 12:899-904.